Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Bulletin Du Cancer|October 4, 2016
[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté]Fanny Dénommé, Marie Kroemer, Philippe Montcuquet, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 27, 2021
Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilationPaul-Michel Mertes, Olivier Collange, Pierre Coliat, et al.
Advanced Materials (Deerfield Beach, Fla.)|December 17, 2023
Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal AntibodiesThomas Gréa, Guillaume Jacquot, Arthur Durand, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
NPJ Breast Cancer|June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortXavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Pageof 21